H omozygous familial hypercholesterolemia (HoFH) is a severe inherited disorder of lipoprotein metabolism resulting mostly from the presence of mutations on both alleles of the LDLR (low-density lipoprotein receptor) or in rare instances biallelic mutations of APOB (apolipoprotein B), PCSK9 (proprotein convertase subtilisin kexin type 9), or the LDLRAP1 (LDLR adaptor protein). [1] [2] [3] These genetic defects sharply reduce the hepatic clearance of low-density lipoproteins (LDL). HoFH patients typically present with LDL cholesterol (LDL-C) plasma concentrations >500 mg/dL (13 mmol/L; although there can be considerable phenotypic variability), leading to premature and often fatal cardiovascular events in the first decades of life. 1, 4 See accompanying editorial on page 481
Conventional lipid-lowering treatments (LLT) currently available, statins and ezetimibe, are moderately effective in HoFH patients because they reduce LDL-C levels by only ≈25%. However, even this modest LDL-C reduction has been shown to delay cardiovascular events and prolong life. 4, 5 These therapies are insufficient to bring HoFH patients to therapeutic target (ie, LDL-C <70 mg/dL [1.8 mmol/L]). Drugs that, respectively, block the synthesis of apoB (mipomersen) or the assembly of nascent apoB-containing lipoproteins (lomitapide) reduce the endogenous production of LDL, thus lowering circulating LDL-C levels independently of residual LDLR activity. 1, 5 Increased hepatic fat (hepatic steatosis) is intrinsic to the mechanisms of action of mipomersen and lomitapide and may limit their use. In addition, mipomersen and lomitapide are not always well tolerated and are extremely costly. LDL apheresis is a further therapeutic option but is not available to all patients because of its cost and often is not sufficient for HoFH patients to reach LDL-C therapeutic goals.
Recently, the TESLA (Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities) and TAUSSIG (Trial Assessing Long Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders) clinical trials showed that the PCSK9 inhibitor evolocumab promotes a 20% to 30% reduction in LDL-C in HoFH patients on top of conventional LLT. 1, 6, 7 Given that PCSK9 is a circulating inhibitor of the LDLR, evolocumab does not lower LDL-C in HoFH patients totally lacking the receptor (receptor-negative). 1, [6] [7] [8] However, for the vast majority of HoFH patients, the activity of the LDLR is reduced but not abrogated (receptor-defective), and evolocumab reduces LDL-C. Interestingly, the response of patients to evolocumab is extremely variable, even among homozygous carriers of identical LDLR genetic defects. 1 To elucidate why HoFH patients with similar LDLR genotypes respond variably to evolocumab, we measured the levels of LDLR expression at their lymphocyte surface. We also investigated the effects of statins, recombinant PCSK9, and a monoclonal antibody targeting PCSK9, on LDLR expression. We found an inverse association between LDLR abundance measured in vitro and the levels of LDL-C and of apoB in the plasma of HoFH patients.
Materials and Methods
Material and Methods are available in the online-only Data Supplement.
Results
Lymphocytes isolated from 1 normolipemic control donor, 1 ligand-defective apoB (LDB) HoFH patient, 5 heterozougous FH (HeFH) patients, and 21 HoFH patients with LDLR genetic defects were incubated sequentially with increasing concentrations of mevastatin, recombinant PCSK9 (rPCSK9), and the PCSK9 inhibitor mAb1/31H4 (mAb1). Baseline LDLR levels measured without mevastatin, rPCSK9, and mAb1 were on average 3.5-fold lower in lymphocytes isolated from HoFH patients (specific mean fluorescence intensity [ΔMFI] 232±109) compared with control (ΔMFI 811±225) and LDB (ΔMFI 885±73) lymphocytes. HeFH lymphocytes displayed intermediate baseline LDLR expression levels (ΔMFI 572±159). Mevastatin treatment significantly increased the expression of the LDLR at the surface of lymphocytes up to maximal ΔMFI levels of 372±171 in HoFH, 1299±123 in HeFH, 1429±177 in control, and 1392±108 in LDB ( Figure 1A ). In contrast, rPCSK9 significantly and dose dependently reduced LDLR cell surface expression down to ΔMFI nadirs of 73±38 in HoFH, 430±97 in HeFH, 320±65 in control, and 326±83 in LDB lymphocytes ( Figure 1A ). Saturating concentrations of the PCSK9 inhibitor mAb1 restored LDLR expression levels back to their maximal ΔMFI levels at 353±155 in HoFH, 1129±175 in HeFH, 1341±191 in control, and 1258±169 in LDB lymphocytes. In each experimental condition, the expression of the LDLR at the plasma membrane was on average 3-to 5-fold lower in HoFH than in control lymphocytes and 2-to 4-fold lower in HoFH than in HeFH lymphocytes.
When HoFH lymphocytes were analyzed with respect to the residual LDLR function associated with their genotypes (listed in Table) , the expression of the LDLR was significantly lower at the surface of lymphocytes isolated from patients carrying 1 negative and 1 defective LDLR allele (ie, the 5 compound heterozygotes FH1/FH2 D206E/V408M), compared with lymphocytes from patients carrying 2 LDLR defective alleles (ie, the 10 true homozygotes FH1/FH1 D206E/D206E; Figure 1B ). Lymphocytes from 4 out of 6 patients carrying other mutations on both LDLR alleles and presenting with milder HoFH phenotypes, as shown by their circulating LDL-C and apoB levels at week 0 (Table) , expressed higher baseline and maximal levels of LDLR at their surface than FH1/FH1 lymphocytes. Lymphocytes from 1 D206E/D154N patient (2 defective LDLR alleles) and from 1 D206E/D461N patient (1 defective and 1 unclassified LDLR alleles) expressed similar LDLR levels than FH1/FH1 lymphocytes ( Figure 1B) . Noteworthy, LDLR cell surface expression levels measured in lymphocytes were variable, even when lymphocytes were isolated from HoFH patients with identical genetic defects. For instance, baseline LDLR expression ranged from ΔMFI levels of 74 to 103 in FH1/FH2 lymphocytes and from ΔMFI levels of 111 to 354 in FH1/FH1 lymphocytes. Maximal LDLR expression ranged from ΔMFI levels of 113 to 195 in FH1/FH2 lymphocytes and from ΔMFI levels of 184 to 607 in FH1/FH1 lymphocytes ( Figure I in the online-only Data Supplement). Of note, mevastatin increased, whereas rPCSK9 reduced and mAb1 restored LDLR cell surface expression in all HoFH lymphocytes tested, proportionally to their baseline LDLR expression levels (r=0.976; P=0.0001 between maximal and baseline LDLR expression levels).
It is well established that PCSK9 inhibition with evolocumab promotes substantial reductions in LDL-C, apoB, and lipoprotein (a) [Lp(a)] in HoFH patients. 1, 6, 7 This was also evident in the 21 HoFH patients included in the present study. Individual responses to treatment were, however, variable, even among patients with identical LDLR mutations (Table) . To determine the molecular bases underpinning these variable responses, we performed a series of correlation analyses between (1) the maximal levels of LDLR expression measured in the lymphocytes of each patient and (2) their levels of LDL-C, apoB, and Lp(a) before (week 0, when patients are on standard LLT) or after evolocumab treatment (week 24, when patient are on standard LLT+420-mg evolocumab Q2W). We found significant negative correlations between maximal LDLR expression levels measured in patients' lymphocytes and their circulating levels of LDL-C at week 0 (r=−0.564; P=0.007) and week 24 (r=−0.700; P=0.0004; Figure 2A ). We also found significant negative correlations between maximal LDLR expression levels of patients' lymphocytes and their plasma apoB concentrations measured at week 0 (r=−0.564; P=0.007) and week 24 (r=−0.667; P=0.001; Figure 2B ). In contrast, the negative correlations between LDLR expression levels and circulating Lp(a) levels measured at week 0 (r=−0.336; P=0.136) and week 24 (r=−0.376; P=0.09) did not reach statistical significance ( Figure 2C ). Noteworthy, there was a wide distribution of apolipoprotein (a) sizes among HoFH patients, ranging from 5 to 35 kringle IV 2 repeats (Table) . We also found a significant negative correlation (r=−0.630; P=0.003) between maximal LDLR levels of primary lymphocytes and the concentrations of apoE measured by liquid chromatographytandem mass spectrometry in plasma samples of HoFH patients (ie, on standard LLT+420-mg evolocumab Q2W). The majority of patients (72%) displayed an apoE3/E3 genotype, 2 patients were E3/E4, and 4 patients were E2/E3 (Table) . To evaluate whether variable apoE genotypes modulate LDL-C, apoB, and Lp(a) levels in HoFH patients, we performed correlations analyses between LDLR expression levels and plasma lipids, separately in the subgroup of 15 patients with an apoE3/E3 genotype ( Figure II . Primary lymphocytes were plated for 24 h in serum-deprived medium with increasing concentrations of mevastatin (Meva) and supplemented or not for the last 4 h of the incubation with rPCSK9 (recombinant proprotein convertase subtilisin kexin type 9) with or without the anti-PCSK9 mAb1 before flow cytometry analysis. LDLR expression levels are expressed in specific mean fluorescence intensity (ΔMFI). Histograms represent mean±SD. *P<0.05; §P<0.05 vs healthy donor lymphocytes under the same experimental conditions. #P<0.05 vs HeFH lymphocytes under the same experimental conditions. ns, P>0.1 vs the Meva 10 µg/mL, no rPCSK9 and no anti-PCSK9 experimental condition.
subgroup of 15 patients with an apoE3/E3 genotype. We did not observe any significant correlation between basal or maximal levels of LDLR expression in lymphocytes and changes in LDL-C levels induced by evolocumab in the cohort of 21 HoFH patients in TAUSSIG (r=0.361; P=0.107 and r=0.325; P=0.150, respectively). However, this correlation became significant when patient J18, the poorest responder to evolocumab, was excluded from the analysis (r=0.567; P=0.009 and r=0.546; P=0.013, respectively; Figure 3) .
When the subgroup of 10 HoFH patients with identical LDLR defects (FH1/FH1) was analyzed separately, we observed a significant negative correlation between the maximal levels of LDLR expression measured in patients lymphocytes and their circulating LDL-C levels at week 0 (r=−0.648; P=0.049) and week 24 (r=−0.8303; P=0.0047). The correlation coefficients between LDLR expression and LDL-C levels at week 0 (r=−0.883; P=0.003) and week 24 (r=−0.950; P=0.0004) were further increased in the subgroup of 9 FH1/ FH1 patients with an apoE3/E3 genotype. The negative correlation between LDLR expression in lymphocytes and plasma apoB at week 0 (r=−0.833; P=0.008) and week 24 (r=−0.933; P=0.0007) also reached statistical significance. The association between LDLR expression and Lp(a) levels was significant at week 0 (r=−0.711; P=0.034) but did not reach statistical significance at week 24 (r=−0.569; P=0.11). As in the entire cohort, the negative association between LDLR expression and apoE levels was significant in FH1/FH1 (r=−0.818; P=0.007). The changes in LDL-C induced by evolocumab treatment in TAUSSIG were positively correlated with basal and maximal LDLR expression of FH1/FH1 lymphocytes (r=0.775; P=0.008 and r=0.737; P=0.015, respectively; Figure 3 ).
Discussion
To understand why HoFH patients, even those with similar LDLR genetic defects, variably respond to evolocumab in clinical trials, we investigated their ability to express apoB indicates apolipoprotein B; D, defective (2%-25% residual LDLR activity); LDB, ligand-defective apoB; LDLR, low-density lipoprotein receptor; N, negative (< 2% residual LDLR activity); TAUSSIG, Trial Assessing Long Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders; and U, unclassified LDLR mutation. *This patient was not on evolocumab at time of blood collection. Δ: percent change from week 0.
the LDLR ex vivo under a wide set of conditions. We first showed that LDLR expression levels were variable in primary lymphocytes isolated from HoFH patients with distinct and similar LDLR mutations. We also showed that the levels of LDLR expression correlated negatively with the circulating levels of LDL-C of patients before and after treatment with evolocumab, demonstrating that residual LDLR functionality and expression are important determinants of LDL clearance in HoFH. We comprehensively investigated LDLR expression at the surface of lymphocytes isolated from patients enrolled in TAUSSIG. As anticipated, LDLR expression was sharply reduced in HoFH lymphocytes compared with non-FH, HeFH, and LDB cells. Not surprisingly, LDLR expression varied widely between lymphocytes isolated from HoFH patients carrying different LDLR mutations. Lymphocytes from FH1/FH2 patients (1 negative and 1 defective LDLR alleles) displayed reduced cell surface LDLR expression compared with lymphocytes from FH1/FH1 patients (2 identical defective LDLR alleles), in line with previous observations made in primary fibroblasts from carriers of those mutations. 8, 9 Even among lymphocytes isolated from patients with identical genetic defects (FH1/FH1), cell surface expression of the LDLR seemed variable, as previously observed in primary fibroblasts. 8 The reasons for these variations within FH1/FH1 lymphocytes are unclear. Given that no neutralizing antibodies were seen in TAUSSIG, it is unlikely that the variability in response to PCSK9 inhibition might be because of a reduced efficacy of evolocumab in some patients. The variations observed may rather result from the presence of epigenetic modifications on the LDLR gene or on the genes controlling LDLR expression such as the SREBPs transcription factors in some patients. 10 These modifications could also promote a differential response to statin treatment.
The significant negative correlations between the expression of the LDLR measured in lymphocytes and the levels of LDL-C and apoB in the plasma of HoFH patients, in particular in the FH1/FH1 subgroup, underpins the important role of residual LDLR activity for the clearance of LDL particles in those individuals. Interestingly, these correlations seemed more pronounced with plasma LDL-C and apoB levels measured after evolocumab treatment. A potential explanation is that the expression and the activity of PCSK9 might greatly vary between individual HoFH subjects, a parameter blunted by evolocumab treatment, because a dose of 420 mg every 2 weeks inhibits 94% to 100% of circulating PCSK9. 1 Besides the residual LDLRs, other receptors that contribute to apoB-containing lipoproteins clearance may also function variably in HoFH patients. Because these receptors are LDLR family members that are also regulated by PCSK9 11, 12 (eg, the LDLR-related protein), their variable functionality could account in part for the variability observed in the LDL-Clowering effects of evolocumab. The presence of distinct apoE isoforms that bind the LDLR with variable affinities 13 could also explain to some extent the substantial range of LDL-C levels and the variability in response to evolocumab observed in HoFH patients with identical LDLR genetic defects. 13, 14 Thus, the correlations coefficients between LDLR expression and LDL-C or apoB100 levels increased when patients with an apoE genotype other than E3/E3 were excluded from our analyses.
Unlike the correlations between LDLR expression in lymphocytes and LDL-C or apoB levels in patients pre-and postevolocumab treatment that reached significance in the whole group and in the FH1/FH1 subgroup, the association between LDLR expression and Lp(a) levels reached significance only in the subgroup of FH1/FH1 patients at a single time point (week 0). This suggests that the residual LDLR activity is probably not a significant determinant of Lp(a) clearance in HoFH, which is further evidenced by the fact that evolocumab reduced Lp(a) but not LDL-C in 2 HoFH patients totally lacking the receptor. 7 The role of the LDLR in Lp(a) clearance remains a controversial issue with recent in vitro studies showing that Lp(a) catabolism is mediated to some extent by the LDLR (when LDLR expression is high) and other studies showing that the LDLR is not involved in Lp(a) uptake. [15] [16] [17] Our study has several limitations. The number of HoFH patients with the same LDLR genotypes included was small. Given the limited amount of lymphocytes available from each patient, we were only able to measure LDLR expression but not LDLR activity (ie, fluorescent LDL uptake). This would have provided valuable information to the study. We have, however, previously shown that LDLR expression and LDLR activity parallel nicely in primary human lymphocytes. 3 In addition, we used lymphocytes to assess LDLR expression ex vivo as a proxy for hepatocytes, 3 a more relevant cell type for LDL and Lp(a) plasma clearance studies. We also assumed that the maximal ability of primary lymphocytes to express the LDLR at their plasma membrane reflects what happens in vivo in patients' hepatocytes on treatment with high doses of statins and evolocumab. Nevertheless, our data clearly indicate that residual activity of the LDLR expression is a major determinant of LDL-C circulating levels in HoFH patients. Enhancing this molecular pathway with evolocumab substantially lowers plasma lipids in these difficult-to-treat patients and will undoubtedly improve their cardiovascular health and their life expectancy.
